Regarding poultry fattening, the use of Sangrovit Extra at its maximum recommended level presented a low risk in terms of consumer impact. Eye irritation was observed as a result of the additive's presence, yet no skin irritation or sensitization effects were found. The FEEDAP Panel recognized the additive's potential to be a respiratory sensitizer and could not discount that possibility. Unprotected individuals handling the additive could be exposed to sanguinarine and chelerythrine. Consequently, minimizing user exposure is crucial for mitigating risk. The environmental impact of Sangrovit Extra, used as a feed additive under the proposed conditions, was deemed negligible. External fungal otitis media For chicken fattening, the potential efficacy of Sangrovit Extra, administered at 45mg/kg within the complete feed, was noted. A conclusion concerning chickens raised for egg-laying or reproduction was expanded to all other poultry types utilized for meat production or egg production.

Acting on the European Commission's solicitation, EFSA was enjoined to furnish a novel scientific opinion on the coccidiostat monensin sodium (Elancoban G200), its use as a feed additive for fattening chickens and turkeys. The Panel's previous conclusions are updated in light of the new data. Monensin sodium is a product of fermentation by a non-genetically modified strain within the Streptomyces sp. genus. This sample, identified with the NRRL B-67924 designation, is important. Genome analysis indicates that the producing strain could potentially represent a novel species within the Streptomyces genus. The final additive was found to be free from the production strain and its DNA. The product's antimicrobial action is confined to monensin's effect. The FEEDAP Panel cannot confirm the safety of monensin sodium from Elancoban G200 in chicken feed for fattening and laying at the proposed maximum level, due to a directly correlated reduction in final body mass with dosage. With the aim of evaluating the toxicological profile of monensin sodium, studies utilized the product from the ATCC 15413 parental strain. The FEEDAP Panel's genome comparison of the two strains revealed toxicological equivalence. This implies that the conclusions regarding Elancoban G200 remain valid for the product using the new production strain, demonstrating its safety for both the environment and the user. The new strain, when assessed for user safety, doesn't introduce any further risk. Turkeys up to sixteen weeks old can safely consume Elancoban G200 monensin sodium at a rate of 100 milligrams per kilogram of feed, potentially controlling coccidiosis with a minimum dosage of 60 milligrams per kilogram of complete feed.

Upon the European Commission's request, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was tasked with formulating a scientific assessment of the effectiveness of the additive containing Companilactobacillus farciminis (formerly Lactobacillus farciminis) CNCM I-3740 (trade name Biacton) for fattening chickens, fattening turkeys, and laying hens. A minimum concentration of 1109 colony-forming units per gram of viable C.farciminis CNCM I-3740 cells defines the additive's preparation. This product is formulated as a zootechnical additive to be integrated into complete feed for fattening chickens, fattening turkeys, and laying hens, at a recommended level of 5108 CFU per kilogram. Previous opinions and the presented data together failed to establish any conclusions about the efficacy of the additive in the various target species. Concerning chickens being fattened, earlier assessments suggested that supplementing with the additive at the prescribed level produced a noticeably larger increase in weight or weight gain for the treated chickens compared to the control group, but this was observed in a limited subset of two studies only. Data from a recent efficacy trial, newly analyzed statistically, have been submitted. Chickens fed Biacton at a level of 85108 CFU/kg feed or above exhibited a substantially better feed conversion ratio compared to the control group and birds receiving the additive at the prescribed dose, as evidenced by the results. According to the panel's findings, Biacton exhibits a potential for efficacy in enhancing the fattening of chickens at the concentration of 85108 CFU per kilogram of complete feed. The conclusion regarding fattening was determined to hold true for turkeys being fattened.

Responding to a request from the European Commission, EFSA was commissioned to provide a scientific report on the safety and effectiveness of potassium ferrocyanide, an anticaking agent included as a functional feed additive, suitable for all animal species. Potassium ferrocyanide is the additive intended for potassium chloride, where the maximum ferrocyanide anion content must not exceed 150 milligrams per kilogram of salt. Potassium chloride supplemented with potassium ferrocyanide, limited to a maximum of 150 milligrams of anhydrous ferrocyanide anions per kilogram, is a safe additive for pigs in fattening and lactation, sheep, goats, salmon, and dogs. Under the proposed conditions, potassium chloride usage is deemed unsafe for fattening chickens, laying hens, turkeys, piglets, veal calves, fattening cattle, dairy cows, horses, rabbits, and cats, lacking a sufficient safety margin. Without data on the dietary potassium chloride intake of other animal species, it is impossible to establish a safe level for supplemented potassium chloride, which includes 150mg ferrocyanide per kilogram of feed. Potassium ferrocyanide's use in animal nutrition presents no cause for consumer safety concerns. Through in vivo studies, it was established that potassium ferrocyanide is not an irritant to the skin and eyes, and it does not cause skin sensitization. Although the additive may have other applications, its nickel content warrants consideration as a respiratory and dermal sensitizer. Although insufficient data exist for the FEEDAP Panel to determine the safety of the additive for soil and marine environments, the proposed application in land-based aquaculture appears safe. At the prescribed usage levels, potassium ferrocyanide is considered an efficacious anticaking agent when combined with potassium chloride.

Following the European Commission's directive, EFSA was required to furnish a scientific opinion on the renewal application for Pediococcus pentosaceus NCIMB 30168, a technological additive for forage intended for use by all animal species. The applicant's submission proves the current market presence of the additive satisfies the existing authorization requirements. The FEEDAP Panel's prior conclusions are unshakeable, with no new evidence presented to alter them. Based on its evaluation, the Panel concludes that the additive, when used under its permitted conditions, remains safe for all animal species, consumers, and the surrounding environment. When considering user safety, the additive's classification should be as a respiratory sensitizer. Determining the additive's potential for skin sensitization, skin irritation, and eye irritation remains impossible. For the authorization renewal, the efficacy of the additive doesn't require evaluation.

Endo-14-beta-xylanase, endo-14-beta-glucanase, and endo-13(4)-beta-glucanase are the components of the feed additive Ronozyme Multigrain G/L, produced by a non-genetically modified variant of Trichoderma reesei (ATCC 74444). This product, categorized as a digestibility enhancer, is authorized for use in fattening and laying poultry, as well as weaned piglets. This scientific opinion examines the request for the renewal of additive authorization pertaining to the species and categories currently authorized. The additive, presently on the market, was shown by the applicant to fulfill the requirements of its authorization. The EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) has examined all new data, and determined that there's no new justification to modify previous conclusions concerning the additive's safety for the animal species/categories, consumers, and the surrounding environment, within its authorized application conditions. For the sake of user safety, the additive is to be considered a potential trigger for respiratory sensitization reactions. In the absence of conclusive data, the Panel could not determine the additive's potential for causing skin and eye irritation, or skin sensitization. No assessment of the additive's effectiveness was required during the renewal process for poultry fattening, laying hens, and weaned piglets' authorizations.

Following the European Commission's directive, the EFSA Panel on Nutrition, Novel Foods, and Food Allergens (NDA) rendered an opinion on 3-fucosyllactose (3-FL) as a novel food (NF), in accordance with Regulation (EU) 2015/2283. Vardenafil order The NF is principally made up of the human-identical milk oligosaccharide (HiMO) 3-FL, but it is also comprised of d-lactose, l-fucose, 3-fucosyllactulose, and a small amount of other related saccharides. Genetically engineered E. coli K-12 DH1 (MDO MAP1834, DSM 4235) strain fermentation yields the NF. Concerning the NF's manufacturing process, composition, and specifications, the provided information does not indicate any safety hazards. The applicant proposes augmenting a collection of foods with NF, specifically infant formula, follow-on formula, foods for specialized medical conditions, and nutritional supplements (FS). For this study, the general population constitutes the target group. The expected daily 3-FL intake, from both the newly proposed and currently authorized uses, combined and at their maximum operational levels, across all population groups, stays below the maximal intake of 3-FL observed in human milk, on a per-kilogram basis in infants. For other groups, the amount of 3-FL ingested by breastfed infants, relative to their body weight, is predicted to pose no harm. The safety of carbohydrate-type compounds structurally similar to 3-FL is also deemed inconsequential. luminescent biosensor The consumption of FS is not recommended if other foods with added 3-FL or human milk are taken during the same day.